

# THE BIOSYNTHESIS OF [ $^{14}\text{C}_5$ ; $^3\text{H}_4$ ]-CHOLESTA-5,7,24-TRIEN-3 $\beta$ -OL AND [ $^{14}\text{C}_5$ ; $^3\text{H}_4$ ]-5 $\alpha$ -CHOLESTA-7,24-DIEN-3 $\beta$ -OL FROM (2R)- AND (2S)- [ $^{14}\text{C}$ ; $^2^3\text{H}$ ]-MEVALONIC ACID BY A YEAST HOMOGENATE

ELIAHU CASPI\*, JACQUES P. MOREAU† and PETER J. RAMM‡

The Worcester Foundation for Experimental Biology, Inc., Shrewsbury, Massachusetts 01545, U.S.A.

(Received 29 April 1974)

## SUMMARY


Incubation of (2R)- and (2S)-[ $^{14}\text{C}$ ;  $^2^3\text{H}$ ]-MVA with a cell free homogenate of yeast resulted in [ $^{14}\text{C}_5$ ;  $^3\text{H}_4$ ]-cholesta-5,7,24-trien-3 $\beta$ -ol and [ $^{14}\text{C}_5$ ;  $^3\text{H}_4$ ]-5 $\alpha$ -cholesta-7,24-dien-3 $\beta$ -ol rather than in  $\text{C}_{28}$  sterols.

## INTRODUCTION


In an earlier publication [1] we described a stereochemical difference between the biosynthesis of cholesterol derivatives in a rat liver preparation and in a yeast homogenate. Described in that paper, among sterols biosynthesized from (2R)-[ $^{14}\text{C}$ ;  $^2^3\text{H}$ ]-mevalonic acid (MVA) and (2S)-[ $^{14}\text{C}$ ;  $^2^3\text{H}$ ]-MVA was a metabolite(s) obtained in significant radioactive yield

which on t.l.c. moved closer to ergosterol [1]. At the time, because of lack of reference samples, the metabolite(s) was not characterized, but on hydrogenation of its acetate(s) [2] it gave 5 $\alpha$ -cholest-7-en-3 $\beta$ -ol acetate I [1]. The "R"-I and "S"-I both retained four tritium atoms. We have established [3] that tritium atoms are located in the "R"-I at 1 $\beta$ , 15 and 26 and in the "S"-I at 1 $\alpha$ , 7 and 26 positions respectively. These results suggested structures II and IV for the metabolite(s). Authentic samples of II and III, and IV and V were prepared [4] and used for the characterization of the product(s). Structure determination was carried out on metabolites derived from (3RS; 2R)-[ $^{14}\text{C}$ ;  $^2^3\text{H}$ ]-MVA.


Incubation of (3RS; 2R)-[ $^{14}\text{C}$ ;  $^2^3\text{H}$ ]-MVA ( $1.1 \times 10^8$  d.p.m. of  $^{14}\text{C}$ ;  $^3\text{H}:^{14}\text{C}$  ratio 10:1) with the yeast




(I) R = Ac; No  $\Delta^{24}$   
 (II) R = H;  $\Delta^{24}$   
 (III) R = Ac;  $\Delta^{24}$




(IV) R = H  
 (V) R = Ac



(VI)



(VII)



(VIII)

\* Correspondence should be addressed to this author.

† Extracted in part from the thesis of J.P.M. to be submitted to the University of Orleans, Orleans, France, in partial fulfillment of requirements of Doctorat D'Etat.

‡ Postdoctoral Fellow, 1967-1969; Present address: Research Department, Roussel Laboratories, Ltd., Covingham Swindon, Wilts SN2 4BE, England.

Table 1. Specific activities of  $^{14}\text{C}$  and  $^3\text{H}:^{14}\text{C}$  ratios of metabolites biosynthesized from (3RS, 2R)-[ $^{14}\text{C}$ ,  $^3\text{H}$ ]-MVA by a yeast homogenate and their transformation products\*

| Compounds  | Specific activity<br>( $\times 10^5$ d.p.m. mmol of $^{14}\text{C}$ ) | Isotopic | $^3\text{H}:^{14}\text{C}$ ratio |       |
|--|---|----------|----------------------------------|-------|
|  |   |          | Atomic                           | Found |
| MVA benzhydrylamide  |   | 10.1     |                                  | 1:1   |
| Squalene**   |   | 9.6      |                                  | 6:6   |
| Squalene Hexachloride                                      | 3.65  | 9.4      | 5.87:6                           | 6:6   |
| Lanosterol   | 4.52  | 9.7      | 6.06:6                           | 6:6   |
| Cholesta-5,7,24-trien-3 $\beta$ -ol acetate (V)            |   |          |                                  |       |
| a from preparative g.l.c.**                                |   | 7.77     | 4.04:5                           | 4:5   |
| b co-crystallization (V)                                   | 2.59  | 7.75     | 4.03:5                           | 4:5   |
| c recovered from (VI)                                      | 2.40  | 7.73     | 4.02:5                           | 4:5   |
| 5 $\alpha$ -Cholest-7-en-3 $\beta$ -ol acetate (I)         | 6.00  | 7.74     | 4.03:5                           | 4:5   |
| Chole-5,7-diene-3 $\beta$ ,24-diol (VII)                   | 0.47  | 7.31     | 3.04:4                           | 3:4   |
| 5 $\alpha$ -Cholesta-7,24-dien-3 $\beta$ -ol acetate (III) | 1.22  | 7.78     | 4.05:5                           | 4:5   |
| 5 $\alpha$ -Cholesta-7,24-dien-3 $\beta$ -ol (II)          | 1.14  | 7.79     | 4.05:5                           | 4:5   |

\* Except for the compounds indicated with (\*\*) all products were crystallized at least three times. The results are the average of counts which did not differ by more than 5%. The specific activities were measured at different dilutions. The calculation of atomic ratios is based on squalene.

homogenate gave after work-up an unsaponifiable residue ( $3.8 \times 10^7$  d.p.m. of  $^{14}\text{C}$ ) which on fractionation by t.l.c. [1] was resolved into "squalene" ( $1.29 \times 10^7$  d.p.m. of  $^{14}\text{C}$ ), "lanosterol" ( $1.07 \times 10^7$  d.p.m. of  $^{14}\text{C}$ ) and "ergosterol" ( $3.8 \times 10^6$  d.p.m. of  $^{14}\text{C}$ ) zones. The squalene and lanosterol fractions were processed in the conventional manner and counted (table).

The "ergosterol zone" ( $3.8 \times 10^6$  d.p.m. of  $^{14}\text{C}$ ) was acetylated and resolved (silica gel-silver nitrate (18%); hexane ethyl-acetate (19:1); developed  $3 \times$ ) into a "dienic" (8% of  $^{14}\text{C}$ ) and a "trienic" (48% of  $^{14}\text{C}$ ) fraction. The "trienic" fraction was further purified by sequential argentation t.l.c. in two systems.

An aliquot of the purified triene was diluted with a small amount of V and analyzed by preparative g.l.c. [5]. The emerging peak of V was collected and its radioactivity measured (table). No separation of radioactivity from mass was noted. Another aliquot of the "trienic" ( $1.5 \times 10^4$  d.p.m. of  $^{14}\text{C}$ ) was diluted with V and crystallized to constant specific activity and constant  $^3\text{H}:^{14}\text{C}$  ratio (table). Hydrogenation of the diluted V gave the expected I (table).

The remainder of the acetylated "trienic" metabolite ( $6.5 \times 10^4$  d.p.m. of  $^{14}\text{C}$ ) was diluted with V (150.2 mg) and converted [6] to the phenyl-triazoline adduct VI (117 mg). Treatment of VI (42 mg) with lithium aluminum hydride (LAH) regenerated IV which was purified and counted as V (table). Ozonolysis of VI (59 mg) and reduction of the ozonide with LAH resulted in VII which was recovered and counted. Authentic VII prepared from VIII by bromination (N-bromosuccinimide), dehydrobromination (collidine), and reduction

with LAH. The presented evidence conclusively established the structure of the metabolite as IV.

The acetylated "dienic" fraction was purified by multiple argentation t.l.c. and co-crystallized with III (table). Treatment of III with LAH gave II which was crystallized to constant specific activity of  $^{14}\text{C}$  and constant  $^3\text{H}:^{14}\text{C}$  ratio (table).

The results establish the structures of the metabolites as II and IV. It is apparent that in the course of the preparation of the homogenate, the C-24 methyl transferase was impaired or destroyed. This was confirmed by the observation that incubation of S-adenosyl-L(methyl- $^{14}\text{C}$ )-methionine ( $5.7 \times 10^7$  d.p.m. of  $^{14}\text{C}$ ) [7] with the yeast homogenate failed to produce radioactive sterols.

*Acknowledgements*—The very generous support of this work by National Institutes of Health (Grants AM-12156, CA13369, and GM19882) and National Science Foundation (Grants GB36201 and GB23801-A1) is gratefully acknowledged.

## REFERENCES

1. Caspi E. and Ramm P.: *Tetrahedron Letters* **3** (1969) 181–185.
2. Bladon P., Fabian J. M., Henbest H. B., Koch K. R. and Wood G. W.: *J. Chem. Soc.* (1951) 2402–2411.
3. The C-15 location of a tritium atom in "R"-I was proven and will be reported. The presence of a tritium atom at C-26, assumed on theoretical grounds, is confirmed in this paper.
4. Moreau J. P., Aberhart D. J. and Caspi E.: *J. org. Chem.* **39** (1974) 2018–2023.

5. HP-7620A instrument; column: 6 feet  $\times$  4 mm ID; 3% SE30 on gas chrom Q (80-100 mesh), t 240°, helium 60 ml/min.
6. Barton D. H. R., Shiori T. and Widdowson D. A.: *J. chem. Soc. Section C, Org. Chem.* (1971) 1968-1974.
7. Lederer E.: *Chem. Soc., Q. Rev.* **23** (1969) 453-481.